India, Jan. 15 -- Weight loss drugs are everywhere right now, with many people seeing positive results for obesity and other chronic metabolic conditions. But experts say their impact goes far beyond simply shrinking the waistline. Emerging evidence suggests these medications may be reshaping how cardiometabolic diseases are treated - offering benefits for heart, liver and metabolic health, not just weight loss.

Dmitry Yaranov, a cardiologist and heart-transplant specialist with expertise in advanced heart failure and mechanical circulatory support, has shared his perspective on GLP-1 medications such as Ozempic, Wegovy and Mounjaro - explaining that their benefits extend well beyond weight loss.

In an Instagram video shared on January ...